Research on the Risk Management of Pharmaceutical Circulation Enterprises -- Taking Sinopharm Holding Co., Ltd as an Example Based on Data Analysis

With the continuous development of the world economy, the health care industry is also improving. However, due to improper risk control, more and more Chinese pharmaceutical enterprises have gradually increased their sales and receivables, and their capital chain turnover situation is very serious. Therefore, risk management is of vital importance for pharmaceutical circulation enterprises. This paper will take Sinopharm Holding Co., Ltd. as an example, combined with the main risk points of the enterprise, to analyze the business situation and financial situation of the company in recent years. Then analyze the debt-paying ability, operating ability and cash flow through its annual financial report. For example, using some empirical study like financial accounting formula: asset-liability ratio, current ratio or net profit margin to analyze the profitability and capacity. Through its accounts receivable and other data to make its capital needs. Finally, through the above analysis, the risk of the entire industry is analyzed and evaluated. To sum up, China's pharmaceutical circulation industry will enter the era of low profit, the industry growth rate slows down, the industry integration continues, the concentration continues to rise.